Time-invariant system

To Elevate Service Excellence, D2 makes Senior Leadership Promotions and Adds New Leaders

Retrieved on: 
Thursday, December 1, 2022

ST. LOUIS, Dec. 01, 2022 (GLOBE NEWSWIRE) -- D2 Solutions is an innovative solution provider that helps empower healthcare stakeholders by leveraging SaaS technology with deep consulting expertise to eliminate key friction points in the marketplace to help drive and achieve better efficiency and improve patient results. As part of D2’s ongoing commitment to service excellence, D2 has made two key promotions and added additional resources to better meet client needs and position itself for expansive growth.

Key Points: 
  • As part of D2s ongoing commitment to service excellence, D2 has made two key promotions and added additional resources to better meet client needs and position itself for expansive growth.
  • D2 is excited to announce the promotion of Laura Reibenstein , PharmD, to the position of Chief Operating Officer.
  • Ms. Reibenstein has been with D2 since 2017, most recently serving as Senior Vice President, Accreditation, Regulatory & Specialty Operations.
  • Laura will be working to develop and strengthen the value D2 Solutions offered to clients, collaborating with senior leadership to propel our direction in alignment with our strategy, stated Dean Erhardt , D2 President & CEO.

Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)

Retrieved on: 
Wednesday, November 30, 2022

The Agency is currently planning to hold an advisory committee meeting to discuss this application.

Key Points: 
  • The Agency is currently planning to hold an advisory committee meeting to discuss this application.
  • SUL-DUR also exhibited a favorable safety profile with statistically significant reduction in nephrotoxicity.
  • Carbapenem-resistant and multidrug-resistant Acinetobacter infections are an urgent and emergent threat due to increasing rates of resistance and few viable treatment options.
  • Our focused and dedicated team looks forward to continuing to work with the FDA throughout the priority review process.

EQS-News: Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment

Retrieved on: 
Wednesday, November 30, 2022

Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License Application (BLA) for pegunigalsidase alfa (PRX102), a drug candidate for the treatment of adult patients with Fabry disease.

Key Points: 
  • Protalix BioTherapeutics, Inc. (NYSE AMERICAN: PLX), an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted a Biologics License Application (BLA) for pegunigalsidase alfa (PRX102), a drug candidate for the treatment of adult patients with Fabry disease.
  • Fabry disease is a rare enzyme deficiency that afflicts 1 in 40,000 to 60,000 people worldwide.
  • Now it is collaborating with the rare disease unit of the Chiesi Group, an Italian-based therapeutic development company, to develop and commercialize PRX-102 for the treatment of Fabry disease.
  • We believe it is important to deliver a potential new treatment option," said Giacomo Chiesi, head of Chiesi Global Rare Diseases, commenting on the resubmission of the BLA.

Nimble Therapeutics names Pete Gough as Chief Scientific Officer

Retrieved on: 
Wednesday, November 30, 2022

Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil.

Key Points: 
  • Nimble Therapeutics, an industry-leading peptide therapeutics company, today announced the appointment of Pete Gough, D. Phil.
  • Prior to joining Nimble, Pete served as the CSO for Inzen Therapeutics, a Flagship company pioneering the newly discovered science of Thanokine Biology.
  • Were excited to welcome Pete to our management team at Nimble, said Jigar Patel, PhD, Founder and CEO of Nimble Therapeutics.
  • Pete has authored/co-authored over 100 scientific papers in peer-reviewed journals and has been an invited speaker at numerous academic institutions and scientific conferences.

Soundbite Medical Solutions Announces Issuance of Two New U.S. Patent Further Expanding Coverage of its Shock Wave Technology

Retrieved on: 
Tuesday, November 29, 2022

Soundbite has been issued 8 US patents to date and continues to enhance its patent portfolio with additional patent applications that will broaden and strengthen its position to leverage shock wave technology in key markets throughout the world.

Key Points: 
  • Soundbite has been issued 8 US patents to date and continues to enhance its patent portfolio with additional patent applications that will broaden and strengthen its position to leverage shock wave technology in key markets throughout the world.
  • Protecting that work and preserving value will establish Soundbite as a leader in its field, said Lori Chmura, President & CEO of Soundbite.
  • The SoundBite Crossing System Peripheral (SCS-P) consists of the reusable SoundBite Console, a single-use sterile SoundBite Active Wire, and their respective accessories.
  • Soundbite is a privately-held medical device company uniquely dedicated to developing meaningful solutions for the interventional treatment of calcific peripheral and coronary arterial diseases.

Open Systems Acquires Tiberium for Automation and Collaboration Technology to Mitigate Cyberthreats with Greater Speed and Accuracy

Retrieved on: 
Tuesday, November 29, 2022

Open Systems will leverage Tiberiums advanced automation and collaboration capabilities to help customers prioritize, decide and act on reducing their risk and mitigating cyberthreats faster than ever before.

Key Points: 
  • Open Systems will leverage Tiberiums advanced automation and collaboration capabilities to help customers prioritize, decide and act on reducing their risk and mitigating cyberthreats faster than ever before.
  • As importantly, automation increases our ability to proactively protect customers, and to expand our advantage over competitive reactive MDR solutions, said Geoff Haydon, CEO of Open Systems.
  • Like Open Systems, Tiberium is a Microsoft Gold Partner and a member of the Microsoft Intelligent Security Association (MISA).
  • We are excited to join forces with Open Systems who shares our vision of automation and real-time collaboration to dramatically improve customers security maturity, said Perry.

AWS' Thomas Edwards, SSIMWAVE'S Abdul Rehman Tackle Sports Streaming Quality In Webinar

Retrieved on: 
Tuesday, November 29, 2022

ONTARIO, Canada, Nov. 29, 2022 /PRNewswire-PRWeb/ -- Dec. 5 event to focus on cloud-based automation, live sports benchmarking

Key Points: 
  • Optimizing live sports video quality to give streaming services a competitive edge will headline the agenda when AWS Principal Solutions Architect Thomas Edwards joins SSIMWAVE CEO and Co-Founder Dr. Abdul Rehman for a special webinar on Monday, December 5.
  • Edwards and Rehman will discuss how video quality has emerged as a critical differentiator in the high-stakes sports media arena, especially when events are delivered by more than one streaming service.
  • The webinar will discuss the current state of streaming sports and how cloud-based automation of video quality can increase viewer engagement and enjoyment, especially for those watching on large-screen HD TVs.
  • SSIMWAVE monitors more than 18 million hours of live video every month across more than 6,000 live channels.

Airborne ISR Market worth $15.6 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 29, 2022

CHICAGO, Nov. 29, 2022 /PRNewswire/ -- The airborne ISR market is projected to grow from USD 12.4 Billion in 2022 to USD 15.6 Billion by 2027, at a CAGR of 4.8% from 2022 to 2027according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Nov. 29, 2022 /PRNewswire/ -- The airborne ISR market is projected to grow from USD 12.4 Billion in 2022 to USD 15.6 Billion by 2027, at a CAGR of 4.8% from 2022 to 2027according to a new report by MarketsandMarkets.
  • Currently, airborne ISR is a critical component in the decision-making process of defense forces across countries.
  • The airborne ISR market is a highly fragmented market with several well-established players.
  • The airborne ISR market is further segmented into defense and homeland security based on the end user.

Airborne ISR Market worth $15.6 Billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 29, 2022

CHICAGO, Nov. 29, 2022 /PRNewswire/ -- The airborne ISR market is projected to grow from USD 12.4 Billion in 2022 to USD 15.6 Billion by 2027, at a CAGR of 4.8% from 2022 to 2027according to a new report by MarketsandMarkets.

Key Points: 
  • CHICAGO, Nov. 29, 2022 /PRNewswire/ -- The airborne ISR market is projected to grow from USD 12.4 Billion in 2022 to USD 15.6 Billion by 2027, at a CAGR of 4.8% from 2022 to 2027according to a new report by MarketsandMarkets.
  • Currently, airborne ISR is a critical component in the decision-making process of defense forces across countries.
  • The airborne ISR market is a highly fragmented market with several well-established players.
  • The airborne ISR market is further segmented into defense and homeland security based on the end user.

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

Retrieved on: 
Tuesday, November 29, 2022

The first patient is expected to be enrolled and dosed in H1 of calendar year 2023, after completing the necessary ethics and regulatory steps.

Key Points: 
  • The first patient is expected to be enrolled and dosed in H1 of calendar year 2023, after completing the necessary ethics and regulatory steps.
  • Urothelial cancer is a type of cancer in the bladder or urinary tract.
  • Under the Agreement, Immutep and Merck KGaA, Darmstadt, Germany will jointly fund the INSIGHT-005 study.
  • Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immuteps large pharmaceutical partners.